Bovine lactoferrin confers antiviral effect against La Crosse Virus by interfering with virus-heparan sulfate proteoglycan binding.

Authors

Masaaki Satoh, Hideki Ebihara, Mutsuyo Takayama-Ito

Published in

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. Pages 103046. Aug 06, 2026. Epub Aug 06, 2026.

Abstract

La Crosse virus (LACV) is a mosquito-borne orthobunyavirus within the California serogroup that primarily causes neuroinvasive disease in pediatric populations in the upper Midwestern, mid-Atlantic, and southeastern states of USA. Despite its substantial impact on public health, no vaccine or effective antiviral treatment has been developed so far. In this study, we investigated the role of the cell-surface heparan sulfate proteoglycan (HSPG) in LACV cell attachment and assessed the in vitro antiviral potential of bovine lactoferrin (bLf), which interacts with both the cell surface molecules and HSPG. Our results demonstrated that HSPG facilitates LACV infection and that bLf inhibits this process in a dose-dependent manner. These observations suggest that the antiviral mechanism of bLf may involve competitive inhibition at HSPG receptor sites, thereby preventing viral attachment to the host cell membrane. This provides further insights into the antiviral activity of bLf against LACV.

PMID:
42562316
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.